WATERTOWN, Mass., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced upcoming data presentations at Infectious Disease Week (IDWeek) 2017, taking place October 4-8 in San Diego, CA. In total, five presentations will be given including pharmacokinetic data from clinical studies supporting eravacycline’s potential use in patients with renal or hepatic impairment as well as from the company’s ongoing oral eravacycline development program.

Details for the data presentations at IDWeek 2017 are as follows:

Eravacycline Data Presentations:
Poster #1829: Pharmacokinetics (PK) of Eravacycline in Subjects with Renal or Hepatic Impairment Compared to Healthy Subjects
Date and time: Saturday, October 7, 12:30 – 2:00 p.m. PT
Session info: 231 - Clinical Study with New Antibiotics and Antifungals, Poster Hall CD

Poster #1832: Impact of Meal Timing on Eravacycline Exposure During the Oral Portion of an IV to Oral Transition Dosing Regimen
Date and time: Saturday, October 7, 12:30 – 2:00 p.m. PT
Session info: 231 - Clinical Study with New Antibiotics and Antifungals, Poster Hall CD

Poster #1209: In Vitro Activity of Eravacycline and Comparator Antimicrobials Against 143 Strains of Bacteroides Species.
Date and time: Friday, October 6, 12:30 – 2:00 p.m. PT
Session info: 147 - Expanded Spectrum – New Antimicrobial Susceptibility Testing, Poster Hall CD

Presentation #866: Eravacycline
Date and time: Thursday, October 5, 3:21 p.m. PT
Speaker: Patrick Horn, MD, Ph.D.
Session info: Symposium 088: New Antibiotics: What’s in the Pipeline?, Room 20ABCD
Follow-up Q&A Session, Friday, October 6, 7:00 – 8:15 a.m. PT; Meet-the-Professor Session 107 – Pipeline 2.0, Room 06DE

Surveillance Data Presentation:
Poster #396: Trends in Resistant Enterobacteriaceae (ENT), Acinetobacter baumannii (ACB) and Extended Spectrum Beta-Lactamase (ESBL) Organisms in Hospitalized Patients in the US: 2011-2016
Date and time: Thursday, October 5, 12:30 – 2:00 p.m. PT
Session info: 052 - HAI: MDRO-GNR/Emerging Resistant Bacterial Pathogens, Poster Hall CD

Additional Activities:

  • Tetraphase will be hosting an Exhibit Booth (#527) at IDWeek 2017 from 10:00 – 2:00 p.m. PT, Thursday, October 5 through Saturday, October 7.
  • Tetraphase has provided an independent educational grant in support of a Continuing Medical Education Lunch Symposium entitled “Evaluating Emerging Options for Complicated and Multi-Drug Resistant Infections: Case-Based Considerations.” It will take place on Wednesday, October 4, 11:00 am – 1:00 pm PT at the Marriott Marquis San Diego Marina, Ballroom F and G.

IDWeek is the combined annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). Full abstracts can be found on the ID Week website at http://www.idweek.org/

About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in a phase 3 clinical program, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information.

Investor Contacts:
Tetraphase Pharmaceuticals
Teri Dahlman

Argot Partners
Maeve Conneighton

Media Contact:
Sam Brown Inc.
Mike Beyer